AntiCancer’s Oral Drug Overcomes Gemcitabine Resistance in Mouse Models of Human Pancreatic Cancer

Newsfeed Image, Light Gray Text On Dark Gray Background
Pancreatic cancer is lethal in about 95% of cases mostly due to failure of first-line therapy gemcitabine.

AntiCancer Inc.’s oral methioninase (AC 00619), which is in late pre-clinical development as an anti-cancer as well as an anti-aging drug, has now been shown to overcome gemcitabine resistance in mouse models of human pancreatic cancer, including AntiCancer’s patient-derived orthotopic xenograft (PDOX®) mouse models. The new results are to be published in the upcoming issue of Cancer Letters. Read more . . .